Cellectis in offering of US$175m ADS following asset swapFrench allogenic CAR-T cell therapy developer Cellectis is set to launch an underwritten public offering of $175m of its American Depositary Shares (ADS), each representing one ordinary share of Cellectis. more ➔
Motif Bio to submit NDA for iclaprim Motif Bio has initiated a NDA rolling submission for iclaprim, a Gram-positive-targeted investigational antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) … more ➔
Takeda announced bid for Shire Japanese drug giant Takeda Pharmaceutical Co. Ltd. has confirmed its intention to make a bid for orphan drug leader and neurology specialist Shire plc. The take-over offer has to be made until 25 April. more ➔
Roche reports 5 deaths after dosing of HemlibraRoche’s US arm Genentech has confirmed a total of 5 deaths in adult patients who were dosed with its to-be hemophilia blockbuster emicizumab (Hemlibra), a BITE antibody that mimics the effect … more ➔
From biorefineries to consumer goodsMore than 400 experts came together at the World Bio Market Conference in Amsterdam to discuss the challenges of successfully implementing bio-based business strategies. more ➔
Ablynx’ SLE antibody vobarilizumab miss endpoint Belgian nanobody maker Ablynx’ IL-6 receptor blocker vobarilizumab didn’t met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive … more ➔
MorphoSys files registration for ADS offeringAntibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (A … more ➔
Deinove to licence antibiotic leads form RedX PharmaFrench antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative … more ➔
Carbios SA Bioeconomy: Germany to lose pole positionThe German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they don’t capitalise on new technology options resulting from the ongoing merger of digital and bio- … more ➔
Eylea met Phase III endpoint in diabetic retinopathy VEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase … more ➔
Carbios SA
